產(chǎn)品詳情
中文名稱:格列吡嗪 | 英文名稱:glipizide |
CAS:29094-61-9 | 純度規(guī)格: 99% |
產(chǎn)品類別: 原料藥中間體 |
2018-12-27
格列吡嗪
glipizide
5 kg/20000RMB
20000
99%
原料藥中間體
我司優(yōu)勢(shì)生產(chǎn)格列吡嗪;
glipizide with GMP ,CEP,DMF CAS:29094-61-9
Glipizide is an oral rapid- and short-acting anti-diabetic drug from the sulfonylurea class. It is classified as a second generation sulfonylurea, which means that it undergoes enterohepatic circulation. Second-generation sulfonylureas are both more potent and have shorter half-lives than the first-generation sulfonylureas.
Originally available in 1984, it is marketed by Pfizer under the brand name Glucotrol in the USA, where Pfizer sells Glucotrol in doses of 5 and 10 milligrams and Glucotrol XL (an extended release form of glipizide) in doses of 2.5, 5, and 10 milligrams.
關(guān)鍵字: 格列吡嗪;glipizide;CAS:29094-61-9 ;格列甲嗪;
公司簡介
Established in May, 2005, Weihai Disu Pharmaceutical Co., Ltd., is a subsidiary of Disha Pharmaceutical
Group, and a national high-tech enterprise.
Relying on the R&D strength of DiSha Pharmaceutical Group, Weihai DiSu Pharmaceutical Co.,Ltd has eight
professional institutes which provide product development, process optimization and other technical services. With
outstanding strength in scientific research and technological innovation ,it is a leader in pharmaceutical intermediates,
veterinary drug, marine biological products and so on.
The company's products strictly enforce the standa
成立日期 |
2005-05-13
(20年)
|
注冊(cè)資本 |
40000萬
|
員工人數(shù) |
500人以上 |
年?duì)I業(yè)額 |
¥ 1億以上 |
主營行業(yè) |
醫(yī)藥中間體,原料藥,天然化學(xué)藥,解熱鎮(zhèn)痛藥,心血管系統(tǒng)用藥 |
經(jīng)營模式 |
工廠 |